These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
181 related items for PubMed ID: 18473714
61. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin. Ayalasomayajula SP, Vaidyanathan S, Kemp C, Prasad P, Balch A, Dole WP. J Clin Pharmacol; 2007 May; 47(5):613-9. PubMed ID: 17442686 [Abstract] [Full Text] [Related]
62. Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient. Kosch M, Barenbrock M, Suwelack B, Schaefer RM, Rahn KH, Hausberg M. Am J Kidney Dis; 2003 May; 41(5):1088-96. PubMed ID: 12722044 [Abstract] [Full Text] [Related]
63. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. Sabia H, Prasad P, Smith HT, Stoltz RR, Rothenberg P. J Cardiovasc Pharmacol; 2001 May; 37(5):502-11. PubMed ID: 11336101 [Abstract] [Full Text] [Related]
64. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Kirchheiner J, Kudlicz D, Meisel C, Bauer S, Meineke I, Roots I, Brockmöller J. Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229 [Abstract] [Full Text] [Related]
65. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Levy RI, Troendle AJ, Fattu JM. Circulation; 1993 Apr; 87(4 Suppl):III45-53. PubMed ID: 8462180 [Abstract] [Full Text] [Related]
66. Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency. Lintott CJ, Scott RS, Bremer JM, Shand BI. Am J Cardiol; 1995 Jul 13; 76(2):97A-101A. PubMed ID: 7604809 [Abstract] [Full Text] [Related]
69. Efficacy and safety of fluvastatin in hypertensive patients. An analysis of a clinical trial database. Peters TK, Mehra M, Muratti EN. Am J Hypertens; 1993 Nov 13; 6(11 Pt 2):340S-345S. PubMed ID: 8297542 [Abstract] [Full Text] [Related]
70. Fluvastatin and perioperative events in patients undergoing vascular surgery. Schouten O, Boersma E, Hoeks SE, Benner R, van Urk H, van Sambeek MR, Verhagen HJ, Khan NA, Dunkelgrun M, Bax JJ, Poldermans D, Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med; 2009 Sep 03; 361(10):980-9. PubMed ID: 19726772 [Abstract] [Full Text] [Related]
72. Fluvastatin plus fish oil are more effective on cardiovascular risk factors than fluvastatin alone. Singer P. Prostaglandins Leukot Essent Fatty Acids; 2005 May 03; 72(5):379-80. PubMed ID: 15850720 [No Abstract] [Full Text] [Related]
73. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Asano T, Hayakawa M. Clin Cancer Res; 2004 Dec 15; 10(24):8648-55. PubMed ID: 15623649 [Abstract] [Full Text] [Related]